title: Datapoints: The ups and downs of dosing second-generation antipsychotics.
authors.affiliation: Department of Psychiatry, New York University School of Medicine, New York City, USA. citrome@nki.rfmh.org
authors.forename: Leslie
authors.initials: L
authors.lastname: Citrome
authors.forename: Ari
authors.initials: A
authors.lastname: Jaffe
authors.forename: Jerome
authors.initials: J
authors.lastname: Levine
mesh_terms: D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000068180:Aripiprazole; D001569:Benzodiazepines / Q000627:therapeutic use; D003987:Dibenzothiazepines / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D006801:Humans; D000077152:Olanzapine; D010879:Piperazines / Q000627:therapeutic use; D011618:Psychotic Disorders / Q000188:drug therapy*; D000069348:Quetiapine Fumarate; D015363:Quinolones / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D010879:Piperazines; D015363:Quinolones; D013844:Thiazoles; D001569:Benzodiazepines; D000069348:Quetiapine Fumarate; C092292:ziprasidone; D000068180:Aripiprazole; D000077152:Olanzapine